{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:32:48Z","timestamp":1740126768371,"version":"3.37.3"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Laryngorhinootologie"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Einleitung\u2002Kleinzellige neuroendokrine Karzinome (KNK) des Larynx sind eine seltene Tumorentit\u00e4t mit schlechter Prognose bei einer 5-Jahres-\u00dcberlebensrate nach Standardtherapie mit prim\u00e4rer Radiochemotherapie (pRCT) von 5\u200a%.<\/jats:p><jats:p>\n          Methoden\u2002Es erfolgte eine systematische Literaturrecherche auf PubMed mit den Suchbegriffen \u201esmall cell neuroendocrine carcinoma\u201c und \u201ehead and neck\u201c sowie die Aufarbeitung von Patientenf\u00e4llen aus unserer Klinik.<\/jats:p><jats:p>\n          Ergebnisse\u2002Die Recherche ergab keine gro\u00dfen randomisierten kontrollierten Studien zur Standardtherapie. Bisherige Therapiestrategien basieren auf den Erfahrungen bei kleinzelligen Karzinomen der Lunge. 0,5\u200a% aller KNK treten im Kopf-Hals-Bereich auf. In unserer Klinik wurden in 12 Jahren 9 KNK diagnostiziert, 2 davon mit laryngealer Manifestation. Wir berichten \u00fcber einen 29-j\u00e4hrigen Patienten mit Erstdiagnose (ED) eines Larynx-KNK im Fr\u00fchjahr 2018. Im Staging zeigten sich zervikale Lymphknotenmetastasen, eine Fernmetastasierung wurde ausgeschlossen. Es erfolgte eine pRCT mit Cisplatin\/Etoposid mit darauffolgender Komplettremission. Im Re-Staging 6 Monate nach ED zeigten sich Metastasen-suspekte Lungenherde. Unter 6 Zyklen palliativer Systemtherapie mit Cyclophosphamid, Adriamycin und Vincristin kam es zu einer partiellen Remission. Nach 12 Monaten erfolgte bei Progress die Therapieumstellung auf den PD-1-Antik\u00f6rper Nivolumab. Der Patient verstarb 22 Monate nach ED an einer tumorbedingten Massenblutung mit Verlegung der Atemwege.<\/jats:p><jats:p>\n          Schlussfolgerung\u2002Bisher existieren keine Studienergebnisse \u00fcber den Einsatz von Nivolumab als Third-Line-Therapie bei KNK. Die Analyse einer NTRK-Fusion (neurotrophe Tyrosin-Rezeptor-Kinase) oder einer Folatrezeptor-Expression sollte erwogen werden zur Evaluation einer Tropomyosin-Rezeptor-Kinase-Inhibitor- oder einer Radionuklidtherapie.<\/jats:p>","DOI":"10.1055\/a-1334-4444","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:05:14Z","timestamp":1609805114000},"page":"981-986","source":"Crossref","is-referenced-by-count":0,"title":["Kleinzelliges neuroendokrines Karzinom des Kopf-Hals-Bereichs: eine \u00dcbersichtsarbeit und Fallserie"],"prefix":"10.1055","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-7737","authenticated-orcid":false,"given":"Felix","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"D\u00f6scher","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Weissinger","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Benckendorff","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Greve","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K.","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Nicole","family":"Theodoraki","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Ulm Medical Centre, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1017\/S0022215115001668","article-title":"Small cell neuroendocrine carcinoma of larynx: case series and literature review","volume":"129","author":"M S Iqbal","year":"2015","journal-title":"J Laryngol Otol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.12788\/jcso.0165","article-title":"Neuroendocrine carcinoma of the larynx with metastasis to the eyelid","volume":"13","author":"H A Assi","year":"2015","journal-title":"J Community Support Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/hed.21162","article-title":"Neuroendocrine neoplasms of the larynx: an overview","volume":"31","author":"A Ferlito","year":"2009","journal-title":"Head Neck"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hed.23666","article-title":"Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A\u00a0meta-analysis of 436 reported cases","volume":"37","author":"T P van der Laan","year":"2015","journal-title":"Head Neck"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000072249","article-title":"Small cell neuroendocrine carcinoma of the larynx: a\u00a0preventable and frustrating disease with a highly aggressive lethal behavior","volume":"65","author":"A Ferlito","year":"2003","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0003489415619179","article-title":"High-Grade Neuroendocrine Carcinoma of the Larynx: The Mayo Clinic Experience","volume":"125","author":"N L Deep","year":"2016","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hed.20797","article-title":"Primary and secondary small cell neuroendocrine carcinoma of the larynx: a review","volume":"30","author":"A Ferlito","year":"2008","journal-title":"Head Neck"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"J George","year":"2015","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/his.12622","article-title":"Myc protein expression correlates with MYC amplification in small-cell lung carcinoma","volume":"67","author":"D H Hwang","year":"2015","journal-title":"Histopathology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1200\/JCO.2016.34.15_suppl.4020","article-title":"Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites","volume":"34","author":"E K Bergsland","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"978676","DOI":"10.1155\/2011\/978676","article-title":"Primary small cell carcinoma of the larynx: report of a rare tumor","volume":"2011","author":"H Singh","year":"2011","journal-title":"Case Rep Oncol Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00405-015-3799-y","article-title":"Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation?","volume":"273","author":"A Coca-Pelaz","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00106-008-1815-x","article-title":"Poorly differentiated neuroendocrine carcinoma of the larynx. Diagnostic features, treatment strategy, and prognosis","volume":"57","author":"M D Jumah","year":"2009","journal-title":"HNO"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032","volume":"14","author":"N Ready","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00428-016-1982-1","article-title":"p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas","volume":"469","author":"L Alos","year":"2016","journal-title":"Virchows Arch"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"S J Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40425-018-0348-4","article-title":"A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a\u00a0case report","volume":"6","author":"W J Ho","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"B Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/jclinpath-2018-205672","article-title":"Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes","volume":"72","author":"R Chetty","year":"2019","journal-title":"J Clin Pathol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2147\/OTT.S177051","article-title":"Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence","volume":"12","author":"B Ricciuti","year":"2019","journal-title":"Onco Targets Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"A Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"E Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Y G Assaraf","year":"2014","journal-title":"Drug Resist Updat"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"J A Ledermann","year":"2015","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2013.03.002","article-title":"Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer","volume":"129","author":"D K Armstrong","year":"2013","journal-title":"Gynecol Oncol"}],"container-title":["Laryngo-Rhino-Otologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1334-4444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:29:39Z","timestamp":1637972979000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1334-4444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,11,26]]},"published-print":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1334-4444","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0935-8943","1438-8685"],"issn-type":[{"type":"print","value":"0935-8943"},{"type":"electronic","value":"1438-8685"}],"subject":[],"published":{"date-parts":[[2021,1,4]]}}}